# China NMPA Drug Inspection - Jilin Huizhongkang Pharmaceutical Co., Ltd. - Eucommia

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-huizhongkang-pharmaceutical-co-ltd/57c36011-e37b-43dc-95b3-31d9958ba945/
Source feed: China

> China NMPA drug inspection for Jilin Huizhongkang Pharmaceutical Co., Ltd. published March 24, 2017. Drug: Eucommia. The State Administration for Market Regulation issued Announcement No. 48 of 2017 on March 24, 2017, revealing significa

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 48 of 2017 from the State Administration of Traditional Chinese Medicine regarding 35 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Jilin Huizhongkang Pharmaceutical Co., Ltd.
- Publication Date: 2017-03-24
- Drug Name: Eucommia
- Inspection Finding: 35 batches of Eucommia ulmoides medicinal slices failed quality tests, with the non-compliant items including content determination and physical properties.
- Action Taken: The relevant provincial (autonomous region, municipality) food and drug administrations have taken control measures such as sealing and seizing products, requiring enterprises to suspend sales and use, recall products, and rectify the situation. Cases of illegal production and sale of substandard products are being investigated and may be subject to heavier penalties.
- Summary: The State Administration for Market Regulation issued Announcement No. 48 of 2017 on March 24, 2017, revealing significant regulatory findings. Inspections, primarily conducted by the Shaanxi Provincial Institute for Food and Drug Control, identified 35 batches of unqualified traditional Chinese medicine decoction pieces, specifically Eucommia ulmoides, from 34 enterprises. One of the implicated companies was Shaanxi Shangluo Panlong Botanical Pharmaceutical Co., Ltd., among many others across various regions. The core issue was that these batches failed to meet established quality standards. In response, provincial food and drug administrations were immediately directed to implement control measures, including sealing and seizing the substandard products, mandating sales and usage suspension, product recalls, and requiring comprehensive rectification from the manufacturers. Operating under Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the State Food and Drug Administration mandated local administrations to investigate these illegal production and sale activities. Manufacturers had the right to object to findings, which would trigger further verification. The regulatory body required public disclosure of investigation results and penalties imposed on involved entities within three months, with severe penalties for confirmed infringements.

Company: https://www.globalkeysolutions.net/companies/jilin-huizhongkang-pharmaceutical-co-ltd/87b765bb-eef5-47d2-88a0-a7887f7bba97/